Click here to get full coverage on Inceptionr LLC Takes Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Inceptionr LLC Takes Position in Kymera Therapeutics, Inc. $KYMR  MarketBeat

Inceptionr LLC Takes Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Click here to get full coverage on Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance

Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Misses Revenue Estimates  Yahoo Finance

Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance

Click here to get full coverage on How Investors Are Reacting To Kymera Therapeutics (KYMR) Launching Phase 2b Trial of STAT6 Degrader - simplywall.st

How Investors Are Reacting To Kymera Therapeutics (KYMR) Launching Phase 2b Trial of STAT6 Degrader  simplywall.st

How Investors Are Reacting To Kymera Therapeutics (KYMR) Launching Phase 2b Trial of STAT6 Degrader - simplywall.st

Click here to get full coverage on New Analyst Forecast: $KYMR Given $80 Price Target - Quiver Quantitative

New Analyst Forecast: $KYMR Given $80 Price Target  Quiver Quantitative

New Analyst Forecast: $KYMR Given $80 Price Target - Quiver Quantitative

Click here to get full coverage on Kymera Therapeutics (KYMR) Price Target Increased by 11.33% to 77.71 - Nasdaq

Kymera Therapeutics (KYMR) Price Target Increased by 11.33% to 77.71  Nasdaq

Kymera Therapeutics (KYMR) Price Target Increased by 11.33% to 77.71 - Nasdaq

Click here to get full coverage on Discipline and Rules-Based Execution in KYMR Response - news.stocktradersdaily.com

Discipline and Rules-Based Execution in KYMR Response  news.stocktradersdaily.com

Discipline and Rules-Based Execution in KYMR Response - news.stocktradersdaily.com

Click here to get full coverage on A Look at Kymera Therapeutics (KYMR) Valuation After Recent Share Price Surge - Sahm

A Look at Kymera Therapeutics (KYMR) Valuation After Recent Share Price Surge  Sahm

A Look at Kymera Therapeutics (KYMR) Valuation After Recent Share Price Surge - Sahm

Click here to get full coverage on Kymera (KYMR) Q3 2025 Earnings Call Transcript - The Globe and Mail

Kymera (KYMR) Q3 2025 Earnings Call Transcript  The Globe and Mail

Kymera (KYMR) Q3 2025 Earnings Call Transcript - The Globe and Mail

Click here to get full coverage on Kymera Therapeutics (NASDAQ: KYMR) to Present at Piper Sandler, Citi and Evercore Events - Stock Titan

Kymera Therapeutics (NASDAQ: KYMR) to Present at Piper Sandler, Citi and Evercore Events  Stock Titan

Kymera Therapeutics (NASDAQ: KYMR) to Present at Piper Sandler, Citi and Evercore Events - Stock Titan

Click here to get full coverage on Kymera Therapeutics (KYMR): Exploring Valuation Following Recent Share Price Momentum - Yahoo Finance

Kymera Therapeutics (KYMR): Exploring Valuation Following Recent Share Price Momentum  Yahoo Finance

Kymera Therapeutics (KYMR): Exploring Valuation Following Recent Share Price Momentum - Yahoo Finance

Click here to get full coverage on Atika Capital Management LLC Buys New Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Atika Capital Management LLC Buys New Holdings in Kymera Therapeutics, Inc. $KYMR  MarketBeat

Atika Capital Management LLC Buys New Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Click here to get full coverage on Barclays Maintains Kymera Therapeutics (KYMR) Overweight Recommendation - Nasdaq

Barclays Maintains Kymera Therapeutics (KYMR) Overweight Recommendation  Nasdaq

Barclays Maintains Kymera Therapeutics (KYMR) Overweight Recommendation - Nasdaq

Click here to get full coverage on How Investors May Respond To Kymera Therapeutics (KYMR) Deepening Net Losses on Rising R&D Spending - simplywall.st

How Investors May Respond To Kymera Therapeutics (KYMR) Deepening Net Losses on Rising R&D Spending  simplywall.st

How Investors May Respond To Kymera Therapeutics (KYMR) Deepening Net Losses on Rising R&D Spending - simplywall.st

Click here to get full coverage on Kymera Therapeutics (NASDAQ: KYMR) completes AD Phase 1b dosing, starts Phase 2b trial - Stock Titan

Kymera Therapeutics (NASDAQ: KYMR) completes AD Phase 1b dosing, starts Phase 2b trial  Stock Titan

Kymera Therapeutics (NASDAQ: KYMR) completes AD Phase 1b dosing, starts Phase 2b trial - Stock Titan

Click here to get full coverage on Ensign Peak Advisors Inc Invests $4.01 Million in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Ensign Peak Advisors Inc Invests $4.01 Million in Kymera Therapeutics, Inc. $KYMR  MarketBeat

Ensign Peak Advisors Inc Invests $4.01 Million in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Click here to get full coverage on A Look at Kymera Therapeutics (KYMR) Valuation After Recent Share Price Surge - simplywall.st

A Look at Kymera Therapeutics (KYMR) Valuation After Recent Share Price Surge  simplywall.st

A Look at Kymera Therapeutics (KYMR) Valuation After Recent Share Price Surge - simplywall.st

Click here to get full coverage on How Investors Are Reacting To Kymera Therapeutics (KYMR) Preclinical Data on Oral IRF5 Degrader in Lupus and RA - Yahoo Finance

How Investors Are Reacting To Kymera Therapeutics (KYMR) Preclinical Data on Oral IRF5 Degrader in Lupus and RA  Yahoo Finance

How Investors Are Reacting To Kymera Therapeutics (KYMR) Preclinical Data on Oral IRF5 Degrader in Lupus and RA - Yahoo Finance

Click here to get full coverage on Intech Investment Management LLC Sells 9,802 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat

Intech Investment Management LLC Sells 9,802 Shares of Kymera Therapeutics, Inc. $KYMR  MarketBeat

Intech Investment Management LLC Sells 9,802 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat

Click here to get full coverage on Kymera Therapeutics, Inc. (KYMR) May Report Negative Earnings: Know the Trend Ahead of Q3 Release - Yahoo Finance

Kymera Therapeutics, Inc. (KYMR) May Report Negative Earnings: Know the Trend Ahead of Q3 Release  Yahoo Finance

Kymera Therapeutics, Inc. (KYMR) May Report Negative Earnings: Know the Trend Ahead of Q3 Release - Yahoo Finance

Click here to get full coverage on Kymera Therapeutics, Inc. $KYMR Shares Acquired by Geode Capital Management LLC - MarketBeat

Kymera Therapeutics, Inc. $KYMR Shares Acquired by Geode Capital Management LLC  MarketBeat

Kymera Therapeutics, Inc. $KYMR Shares Acquired by Geode Capital Management LLC - MarketBeat

Click here to get full coverage on Earnings To Watch: Kymera Therapeutics Inc (KYMR) Reports Q2 2025 Result - Yahoo Finance

Earnings To Watch: Kymera Therapeutics Inc (KYMR) Reports Q2 2025 Result  Yahoo Finance

Earnings To Watch: Kymera Therapeutics Inc (KYMR) Reports Q2 2025 Result - Yahoo Finance

Click here to get full coverage on Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance

Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Misses Revenue Estimates  Yahoo Finance

Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance

Click here to get full coverage on Kymera Therapeutics (NASDAQ:KYMR) Sets New 1-Year High - Still a Buy? - MarketBeat

Kymera Therapeutics (NASDAQ:KYMR) Sets New 1-Year High - Still a Buy?  MarketBeat

Kymera Therapeutics (NASDAQ:KYMR) Sets New 1-Year High - Still a Buy? - MarketBeat

Click here to get full coverage on Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance

Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release  Yahoo Finance

Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance

Click here to get full coverage on Kymera Therapeutics (KYMR): Evaluating Valuation Following Clinical Progress, Preclinical Data, and Expanded Partnerships - Sahm

Kymera Therapeutics (KYMR): Evaluating Valuation Following Clinical Progress, Preclinical Data, and Expanded Partnerships  Sahm

Kymera Therapeutics (KYMR): Evaluating Valuation Following Clinical Progress, Preclinical Data, and Expanded Partnerships - Sahm

Click here to get full coverage on SG Americas Securities LLC Buys Shares of 22,065 Kymera Therapeutics, Inc. $KYMR - MarketBeat

SG Americas Securities LLC Buys Shares of 22,065 Kymera Therapeutics, Inc. $KYMR  MarketBeat

SG Americas Securities LLC Buys Shares of 22,065 Kymera Therapeutics, Inc. $KYMR - MarketBeat

Click here to get full coverage on Truist Financial Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $80 - 富途牛牛

Truist Financial Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $80  富途牛牛

Truist Financial Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $80 - 富途牛牛

Click here to get full coverage on Kymera Trades Near 52-Week High: Time to Buy, Sell or Hold the Stock? - Yahoo Finance

Kymera Trades Near 52-Week High: Time to Buy, Sell or Hold the Stock?  Yahoo Finance

Kymera Trades Near 52-Week High: Time to Buy, Sell or Hold the Stock? - Yahoo Finance

Click here to get full coverage on Kymera Therapeutics (KYMR): Evaluating Valuation Following Clinical Progress, Preclinical Data, and Expanded Partnerships - simplywall.st

Kymera Therapeutics (KYMR): Evaluating Valuation Following Clinical Progress, Preclinical Data, and Expanded Partnerships  simplywall.st

Kymera Therapeutics (KYMR): Evaluating Valuation Following Clinical Progress, Preclinical Data, and Expanded Partnerships - simplywall.st

Click here to get full coverage on Clinical-Stage Biotech Kymera Therapeutics Sets Q2 Earnings Date: Key Updates Expected on Immunology Pipeline - Stock Titan

Clinical-Stage Biotech Kymera Therapeutics Sets Q2 Earnings Date: Key Updates Expected on Immunology Pipeline  Stock Titan

Clinical-Stage Biotech Kymera Therapeutics Sets Q2 Earnings Date: Key Updates Expected on Immunology Pipeline - Stock Titan

Click here to get full coverage on Truist Securities Raises Price Target for Kymera Therapeutics (K - GuruFocus

Truist Securities Raises Price Target for Kymera Therapeutics (K  GuruFocus

Truist Securities Raises Price Target for Kymera Therapeutics (K - GuruFocus

Click here to get full coverage on Kymera Therapeutics Inc (KYMR) Q2 2025 Earnings Call Highlights: Strategic Collaborations and ... - Yahoo Finance

Kymera Therapeutics Inc (KYMR) Q2 2025 Earnings Call Highlights: Strategic Collaborations and ...  Yahoo Finance

Kymera Therapeutics Inc (KYMR) Q2 2025 Earnings Call Highlights: Strategic Collaborations and ... - Yahoo Finance

Click here to get full coverage on Kymera is a new Outperform at RBC Capital Markets on lead asset - Seeking Alpha

Kymera is a new Outperform at RBC Capital Markets on lead asset  Seeking Alpha

Kymera is a new Outperform at RBC Capital Markets on lead asset - Seeking Alpha

Click here to get full coverage on Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Rating of "Moderate Buy" by Analysts  MarketBeat

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Click here to get full coverage on Did Kymera’s (KYMR) KT-579 Lupus and RA Data Just Shift the Immunology Investment Narrative? - Sahm

Did Kymera’s (KYMR) KT-579 Lupus and RA Data Just Shift the Immunology Investment Narrative?  Sahm

Did Kymera’s (KYMR) KT-579 Lupus and RA Data Just Shift the Immunology Investment Narrative? - Sahm

Click here to get full coverage on Kymera Therapeutics (KYMR) Advances STAT6 Degrader Program with New Trial - GuruFocus

Kymera Therapeutics (KYMR) Advances STAT6 Degrader Program with New Trial  GuruFocus

Kymera Therapeutics (KYMR) Advances STAT6 Degrader Program with New Trial - GuruFocus

Click here to get full coverage on Kymera Therapeutics (KYMR) Losses Worsen, Challenging Bullish Narratives on Profit Timeline - simplywall.st

Kymera Therapeutics (KYMR) Losses Worsen, Challenging Bullish Narratives on Profit Timeline  simplywall.st

Kymera Therapeutics (KYMR) Losses Worsen, Challenging Bullish Narratives on Profit Timeline - simplywall.st

Click here to get full coverage on Kymera Therapeutics (KYMR) director group buys $13.9 million in stock - Investing.com

Kymera Therapeutics (KYMR) director group buys $13.9 million in stock  Investing.com

Kymera Therapeutics (KYMR) director group buys $13.9 million in stock - Investing.com

Click here to get full coverage on Candriam S.C.A. Invests $6.73 Million in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Candriam S.C.A. Invests $6.73 Million in Kymera Therapeutics, Inc. $KYMR  MarketBeat

Candriam S.C.A. Invests $6.73 Million in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Click here to get full coverage on KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update - Nasdaq

KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update  Nasdaq

KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update - Nasdaq

Click here to get full coverage on Kymera Therapeutics (NASDAQ: KYMR) to report third quarter 2025; webcast at 8:30 a.m. ET - Stock Titan

Kymera Therapeutics (NASDAQ: KYMR) to report third quarter 2025; webcast at 8:30 a.m. ET  Stock Titan

Kymera Therapeutics (NASDAQ: KYMR) to report third quarter 2025; webcast at 8:30 a.m. ET - Stock Titan

Click here to get full coverage on Kymera Therapeutics (NASDAQ: KYMR) to join 5 November investor conferences; webcasts - Stock Titan

Kymera Therapeutics (NASDAQ: KYMR) to join 5 November investor conferences; webcasts  Stock Titan

Kymera Therapeutics (NASDAQ: KYMR) to join 5 November investor conferences; webcasts - Stock Titan

Click here to get full coverage on New Analyst Forecast: $KYMR Given 'Outperform' Rating - Quiver Quantitative

New Analyst Forecast: $KYMR Given 'Outperform' Rating  Quiver Quantitative

New Analyst Forecast: $KYMR Given 'Outperform' Rating - Quiver Quantitative

Click here to get full coverage on Universal Beteiligungs und Servicegesellschaft mbH Purchases 22,392 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat

Universal Beteiligungs und Servicegesellschaft mbH Purchases 22,392 Shares of Kymera Therapeutics, Inc. $KYMR  MarketBeat

Universal Beteiligungs und Servicegesellschaft mbH Purchases 22,392 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat

Click here to get full coverage on Guggenheim Assumes Buy Rating for Kymera Therapeutics (KYMR) | K - GuruFocus

Guggenheim Assumes Buy Rating for Kymera Therapeutics (KYMR) | K  GuruFocus

Guggenheim Assumes Buy Rating for Kymera Therapeutics (KYMR) | K - GuruFocus

Click here to get full coverage on Kymera Therapeutics Advances KT-621 Trials with Upcoming Phase 1b Data in Atopic Dermatitis and Phase 2b Initiation for Asthma - Quiver Quantitative

Kymera Therapeutics Advances KT-621 Trials with Upcoming Phase 1b Data in Atopic Dermatitis and Phase 2b Initiation for Asthma  Quiver Quantitative

Kymera Therapeutics Advances KT-621 Trials with Upcoming Phase 1b Data in Atopic Dermatitis and Phase 2b Initiation for Asthma - Quiver Quantitative

Click here to get full coverage on Insider Sale: Director at $KYMR Sells 5,000 Shares - Quiver Quantitative

Insider Sale: Director at $KYMR Sells 5,000 Shares  Quiver Quantitative

Insider Sale: Director at $KYMR Sells 5,000 Shares - Quiver Quantitative

Click here to get full coverage on Kymera Therapeutics (KYMR) Receives New "Outperform" Rating from Mizuho | KYMR Stock News - GuruFocus

Kymera Therapeutics (KYMR) Receives New "Outperform" Rating from Mizuho | KYMR Stock News  GuruFocus

Kymera Therapeutics (KYMR) Receives New "Outperform" Rating from Mizuho | KYMR Stock News - GuruFocus

Click here to get full coverage on Decoding Kymera Therapeutics Inc (KYMR): A Strategic SWOT Insigh - GuruFocus

Decoding Kymera Therapeutics Inc (KYMR): A Strategic SWOT Insigh  GuruFocus

Decoding Kymera Therapeutics Inc (KYMR): A Strategic SWOT Insigh - GuruFocus

Click here to get full coverage on Truist Financial Keeps Their Buy Rating on Kymera Therapeutics (KYMR) - The Globe and Mail

Truist Financial Keeps Their Buy Rating on Kymera Therapeutics (KYMR)  The Globe and Mail

Truist Financial Keeps Their Buy Rating on Kymera Therapeutics (KYMR) - The Globe and Mail

Click here to get full coverage on Kymera Therapeutics Inc (KYMR) Q3 2025 Earnings Report Preview: What to Look For - GuruFocus

Kymera Therapeutics Inc (KYMR) Q3 2025 Earnings Report Preview: What to Look For  GuruFocus

Kymera Therapeutics Inc (KYMR) Q3 2025 Earnings Report Preview: What to Look For - GuruFocus

Click here to get full coverage on TD Cowen Maintains Kymera Therapeutics(KYMR.US) With Buy Rating - 富途牛牛

TD Cowen Maintains Kymera Therapeutics(KYMR.US) With Buy Rating  富途牛牛

TD Cowen Maintains Kymera Therapeutics(KYMR.US) With Buy Rating - 富途牛牛

Click here to get full coverage on RBC Capital Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $70 - 富途牛牛

RBC Capital Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $70  富途牛牛

RBC Capital Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $70 - 富途牛牛

Click here to get full coverage on Kymera Therapeutics (KYMR): Citigroup Raises Price Target, Maint - GuruFocus

Kymera Therapeutics (KYMR): Citigroup Raises Price Target, Maint  GuruFocus

Kymera Therapeutics (KYMR): Citigroup Raises Price Target, Maint - GuruFocus

Click here to get full coverage on Kymera added to Citi catalyst watch list on atopic dermatitis asset data readout (KYMR:NASDAQ) - Seeking Alpha

Kymera added to Citi catalyst watch list on atopic dermatitis asset data readout (KYMR:NASDAQ)  Seeking Alpha

Kymera added to Citi catalyst watch list on atopic dermatitis asset data readout (KYMR:NASDAQ) - Seeking Alpha

Click here to get full coverage on Kymera Therapeutics to Announce Q3 2025 Financial Results and Host Video Conference on November 4, 2025 - Quiver Quantitative

Kymera Therapeutics to Announce Q3 2025 Financial Results and Host Video Conference on November 4, 2025  Quiver Quantitative

Kymera Therapeutics to Announce Q3 2025 Financial Results and Host Video Conference on November 4, 2025 - Quiver Quantitative

Click here to get full coverage on Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance

Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings Call Highlights: Strategic Advances and ...  Yahoo Finance

Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance

Click here to get full coverage on Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline - Yahoo Finance

Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline  Yahoo Finance

Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline - Yahoo Finance

Click here to get full coverage on Kymera Therapeutics (NASDAQ:KYMR) Coverage Initiated by Analysts at Guggenheim - MarketBeat

Kymera Therapeutics (NASDAQ:KYMR) Coverage Initiated by Analysts at Guggenheim  MarketBeat

Kymera Therapeutics (NASDAQ:KYMR) Coverage Initiated by Analysts at Guggenheim - MarketBeat

Click here to get full coverage on Kymera Therapeutics (KYMR) Gains Attention with Upcoming Data Re - GuruFocus

Kymera Therapeutics (KYMR) Gains Attention with Upcoming Data Re  GuruFocus

Kymera Therapeutics (KYMR) Gains Attention with Upcoming Data Re - GuruFocus

Click here to get full coverage on Kymera Therapeutics’s Gollob sells $186k in shares - Investing.com

Kymera Therapeutics’s Gollob sells $186k in shares  Investing.com

Kymera Therapeutics’s Gollob sells $186k in shares - Investing.com

Click here to get full coverage on Guggenheim assumes coverage on Kymera stock with Buy rating, $90 target - Investing.com

Guggenheim assumes coverage on Kymera stock with Buy rating, $90 target  Investing.com

Guggenheim assumes coverage on Kymera stock with Buy rating, $90 target - Investing.com

Click here to get full coverage on Kymera Therapeutics director Albers sells $295k in shares - Investing.com

Kymera Therapeutics director Albers sells $295k in shares  Investing.com

Kymera Therapeutics director Albers sells $295k in shares - Investing.com

Click here to get full coverage on Kymera Therapeutics (KYMR) Analyst Rating Update: HC Wainwright - GuruFocus

Kymera Therapeutics (KYMR) Analyst Rating Update: HC Wainwright  GuruFocus

Kymera Therapeutics (KYMR) Analyst Rating Update: HC Wainwright - GuruFocus

Click here to get full coverage on Kymera Therapeutics - Intriguing Degradation Thesis, But A Bit Powder Puff (NASDAQ:KYMR) - Seeking Alpha

Kymera Therapeutics - Intriguing Degradation Thesis, But A Bit Powder Puff (NASDAQ:KYMR)  Seeking Alpha

Kymera Therapeutics - Intriguing Degradation Thesis, But A Bit Powder Puff (NASDAQ:KYMR) - Seeking Alpha

Click here to get full coverage on Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders - Business Wire

Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders  Business Wire

Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders - Business Wire

Click here to get full coverage on BTIG Maintains 'Buy' Rating on KYMR, Raises Price Target to $75 - GuruFocus

BTIG Maintains 'Buy' Rating on KYMR, Raises Price Target to $75  GuruFocus

KYMR

Price Chart

Key Statistics

Technicals

About KYMR

Latest News

Inceptionr LLC Takes Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat

Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance

How Investors Are Reacting To Kymera Therapeutics (KYMR) Launching Phase 2b Trial of STAT6 Degrader - simplywall.st

Advanced Charts

Top Gainers

Top Losers